An anthracycline antibiotic that has formula C27H29NO11.
Chemical ID:
MESH:D004317
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Fungal Polysaccharides inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; GW 6471 inhibits the reaction [SIRT6 protein inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]]; SIRT6 protein inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]
Doxorubicin results in increased expression of CDKN1A; Doxorubicin results in increased expression of CDKN1A mRNA; Doxorubicin results in increased expression of CDKN1A protein
[[MT1 protein co-treated with MT2 protein] affects the susceptibility to Doxorubicin] which affects the expression of CDKN1A mRNA; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of ACTA2 protein]; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of IFNG protein]; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of IL6 protein]; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of NPPA mRNA]; CDKN1A gene mutant form inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; SIRT6 protein inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TRP53 gene mutant form inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]
1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; 3-methyladenine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; [dimethyl sulfone co-treated with Doxorubicin] affects the expression of CDKN1A mRNA; [Doxorubicin co-treated with Paclitaxel] results in increased expression of CDKN1A protein; [Doxorubicin co-treated with Resveratrol] results in increased expression of CDKN1A mRNA; [Doxorubicin co-treated with Resveratrol] results in increased expression of CDKN1A protein; [RELA protein affects the expression of CDKN1A protein] which affects the susceptibility to Doxorubicin; Acetylcysteine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; bisphenol A affects the reaction [Doxorubicin affects the expression of CDKN1A mRNA]; bisphenol A inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; Caffeine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; CDC25C protein inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; CDKN1A protein inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; CDKN1A protein results in decreased susceptibility to [Doxorubicin co-treated with TNF protein]; CGK 733 inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; Chloroquine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; dimethyl sulfone affects the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; Doxorubicin affects the reaction [RELA protein binds to CDKN1A promoter]; Doxorubicin affects the reaction [RELA protein results in increased expression of CDKN1A mRNA]; Doxorubicin inhibits the reaction [KDM8 protein binds to CDKN1A promoter]; Doxorubicin promotes the reaction [TP53 protein binds to CDKN1A promoter]; Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein; FHL2 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]; Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of CDKN1A protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; Glutathione inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; KDM8 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]; Loperamide promotes the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein]; RV 538 inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; SPHK2 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]; tempol promotes the reaction [CDKN1A protein results in increased susceptibility to Doxorubicin]; TNF protein inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; TP53 affects the reaction [Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein]; TP53 affects the reaction [nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein]]; TP53 gene mutant form inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TP53 protein affects the reaction [Doxorubicin affects the reaction [RELA protein results in increased expression of CDKN1A mRNA]]; TP53 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TP53 protein affects the reaction [FHL2 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]]; TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TRIM28 protein modified form inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; XAF1 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]
